GlassScriptPhysician profile
Jennifer Arnold
NPI 1104209238
$8,305.13
in general payments reported to CMS, 2019-2025
56 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $2,169 · 2023: $1,995 · 2024: $1,974 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,620 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,620.39 |
| Education | $259.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,316.99 | 2021-2025 | Erleada, Akeega, Darzalex |
| Novartis Pharmaceuticals Corporation | $688.26 | 2022-2025 | |
| Pfizer INC. | $469.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $448.55 | 2022-2025 | Calquence, Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $429.41 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $363.08 | 2022-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Amgen INC. | $346.76 | 2021-2025 | Kyprolis |
| Eisai INC. | $318.63 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $277.87 | 2022-2023 | Opdivo |
| Astellas Pharma US INC | $264.47 | 2023-2025 | Padcev, Xtandi |
| Janssen Scientific Affairs, LLC | $251.41 | 2023-2024 | Erleada, Akeega |
| Genzyme Corporation | $202.93 | 2021-2025 | |
| Daiichi Sankyo INC. | $190.48 | 2021-2023 | Enhertu |
| Aveo Pharmaceuticals, INC. | $189.16 | 2022-2024 | |
| Medtronic, INC. | $173.02 | 2025 | Synchromedii |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $168.21 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $162.38 | 2021-2025 | Reblozyl |
| Incyte Corporation | $154.94 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $147.44 | 2022 | |
| Abbvie INC. | $126.82 | 2021-2025 | |
| Lilly USA, LLC | $118.07 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Genentech USA, INC. | $116.34 | 2022-2025 | Polivy, Tecentriq, Phesgo |
| Exelixis INC. | $112.54 | 2023-2025 | Cabometyx |
| Seagen INC. | $108.73 | 2023-2025 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $98.86 | 2022-2024 | Libtayo |
| Servier Pharmaceuticals LLC | $97.23 | 2023 | |
| Pharmaessentia USA Corporation | $83.75 | 2022-2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $74.10 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $73.86 | 2022-2023 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $65.28 | 2022-2025 | |
| Puma Biotechnology, INC. | $62.77 | 2023-2025 | Nerlynx |
| Array Biopharma INC | $61.33 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Jazz Pharmaceuticals INC. | $54.98 | 2022-2024 | |
| Foundation Medicine, INC. | $40.11 | 2022-2023 | |
| Genmab U.S., INC. | $33.94 | 2023-2024 | Tivdak |
| Mirati Therapeutics, INC. | $33.33 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $29.11 | 2022 | |
| Sumitomo Pharma America, INC. | $28.53 | 2023-2024 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $26.03 | 2025 | Danziten |
| Ipsen Biopharmaceuticals, INC | $25.20 | 2024 | Onivyde |
| Abbott Laboratories | $24.56 | 2023 | Freestyle Libre 3 |
| Morphosys, US INC. | $19.77 | 2022 | |
| Beone Medicines USA, INC. | $19.20 | 2025 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $19.19 | 2025 | Revuforj |
| Karyopharm Therapeutics INC. | $18.67 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.12 | 2023 | Qinlock |
| Taiho Oncology, INC. | $17.96 | 2024 | |
| Sandoz INC. | $17.32 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.29 | 2024 | Adstiladrin |
| Tempus Ai, INC | $16.69 | 2024 | |
| Apellis Pharmaceuticals, INC. | $14.94 | 2025 | Empaveli |
| Cti Biopharma Corp. | $14.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.87 | 2025 | Ultomiris |
| Coherus Oncology, INC. | $13.32 | 2023 | |
| Kite Pharma, INC. | $13.24 | 2024 | Yescarta |
| Beigene USA, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.